ArticleJournal of experimental & clinical cancer research : CR2019

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.

Elaine Reguera-Nuñez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.